Background {#Sec1}
==========

In patients diagnosed with HIV-1 (human immunodeficiency virus type 1), immunodeficiency significantly increases the risk of disease caused by pathogens that expand as a consequence of reduced level of T lymphocyte (LT) CD4 + cells, and pathogenicity is usually controlled by humoral and cellular immune responses \[[@CR1]\]. However, since the introduction of antiretroviral drugs and effective regimens of antiretroviral therapy (highly active antiretroviral therapy -- HAART), the prognosis for humans infected with HIV-1 has been significantly improved, thereby enabling them to lead active lives with outdoor activities that increase the risk of tick infestation \[[@CR2]\].

Pathogens that cause tick-borne diseases (TBDs) constitute a significant problem for the public health. The observed increase of tick count, their high activity in the natural environment and in the urban area increases the risk of tick-borne infections \[[@CR3]--[@CR5]\]. In Europe, *Ixodes ricinus* is the most prevalent and widely distributed tick species which serves as the most important vector for several microbial pathogens, including *Borrelia, Anaplasma, Babesia* and *Rickettsia* \[[@CR6]\]. Additionally, new tick-borne pathogens, *Candidatus* Neoehrlichia mikurensis (CNM) and *Borrelia myiamotoi*, have been observed in ticks as well as in humans in Europe, e.g. Poland \[[@CR7]--[@CR9]\]. So far in Europe, from the wide range of tick-borne pathogens, only *Borrelia*, *Babesia* and *Rickettsia* infections have been detected in HIV-infected humans \[[@CR10]--[@CR14]\].

*Borrelia burgdorferi* spirochetes comprise the etiological agent of Lyme disease, the most common tick-borne disease in the USA and Europe \[[@CR15]\]. The most common clinical symptom of the early phase of infection is *erythema migrans* (EM). In the course of disseminated infection, spirochetes penetrate into body tissues, especially skin, central nervous system, joints and heart. *Borrelia burgdorferi* sensu stricto is the sole causative agent of Lyme disease in North America \[[@CR15]\]. In Europe, at least five species are considered to be pathogenic for humans (*B. afzelii*, *B. garinii*, *B burgdorferi*, *B. spielmanii*, *B. bavariensis*), resulting in much higher than in the United States of America variety of clinical symptoms of Lyme disease \[[@CR15]\]. Borreliosis is a rare co-infection in HIV-positive patients, and till now, it has only few cases have been reported \[[@CR10]--[@CR12], [@CR16]--[@CR18]\]. Most cases were diagnosed as early infections, and neuroborreliosis has been confirmed in patients from the Netherlands and Sweden \[[@CR11], [@CR12]\]. Until now it remains unclear whether HIV-positive persons are at increased risk of acquiring or atypical course of tick-born infections and studies in this area are scarce. However it could be expected that HIV-1 and *Borrelia* co-infection is more common than it has been described so far \[[@CR12]\]. Diagnosing of Lyme disease using serology- based methods in HIV-positive patients is believed to be complicated due to their reduced positive predictive value of serology \[[@CR19]\]. Currently, thanks to the improvement of the effectiveness of treatment, the majority of HIV positive patients has a significant improvement in the immune system function and consequently the positive predictive value (PPV) risk for serological tests is significantly lower. Moreover, false positive serologic findings are described in patients with neurological infections with other spirochetes such as *Treponema pallidum* \[[@CR20]\].

Babesiosis is a tick-borne disease caused in humans by protozoa of the *Babesia* genus, mainly *B. microti* in the USA and *B. divergens* in Europe (isolated cases of infection with *B. microti* and *B. venetorum* have been noted). Furthermore, transfusion-transmitted babesiosis has been recognized, and a few congenital human cases due to *B. microti* have been documented \[[@CR21]--[@CR23]\]. Babesiosis in HIV-infected individuals was observed to date in the United States of America \[[@CR24]--[@CR29]\], and one case was noted in Europe (Spain; \[[@CR13]\]). Molecular studies have confirmed infection with *B. microti* (the USA; \[[@CR28], [@CR29]\]) or *B. divergens* (Spain, \[[@CR13]\]). In a few instances, babesiosis was observed either in asplenic, HIV-positive patients \[[@CR25], [@CR26]\], or its symptoms appeared only after splenectomy \[[@CR13]\]. In HIV-infected humans a long-term chronic phase of infection lasting several months despite treatment was observed with relapses which required blood transfusions because of the high parasitemia (8.5% of infected red blood cells, iRBC; \[[@CR29]\]).

Tick-borne rickettsiosis is caused by intracellular bacteria belonging to the spotted fever group (SFG) of the Rickettsiaceae family. The main clinical manifestations of a rickettsial syndrome in humans are fever, rash, and eschar at the site of the tick bite ('tache noire') \[[@CR30]\]. Isolated cases of Mediterranean spotted fever (MSF), caused mainly by *R. conorii* and *R. monacensis*, have been reported in HIV-infected humans \[[@CR14], [@CR31]\]. In some cases, primary HIV infection can mimic MSF presentation \[[@CR31]\].

The studies on the occurrence and diversity of tick-borne infections in HIV-infected individuals have been few, and the subject has been relatively neglected when compared with other infections associated with HIV. Non-specific symptoms of tick-borne diseases poses a challenge in clinical care and may lead to misdiagnosis, especially in HIV-positive patients, who often present with many clinical symptoms. Additionally, in immunocompromised patients, prolonged prepatent periods with a significant delay of antibody production may occur, and the results of a serological test may be misinterpreted \[[@CR32], [@CR33]\]. The purpose of this study was to investigate the prevalence and risk for tick-borne infection in HIV-1-infected individuals in Poland, where tick-borne diseases are endemic. To the best of our knowledge, this is the first molecular study on the occurrence of the most frequent pathogens transmitted by ticks (*Borrelia* spp., *Babesia* spp., *Rickettsia* spp., *A. phagocytophilum*, *Candidatus* Neoehrlichia spp.) in HIV-1-infected humans.

Methods {#Sec2}
=======

Blood samples/selection of patients {#Sec3}
-----------------------------------

The retrospective study was conducted on HIV-positive patients who had no history of tick bite and no clinical manifestation characteristic for tick-borne diseases. In 2013, blood samples were collected from 148 patients routinely followed at the HIV Outpatients' Clinic of the Hospital for Infectious Diseases in Warsaw. Written informed consent was obtained from all patients and the study protocol followed ethical guidelines of the 2013 Declaration of Helsinki. The study was approved by the Internal Review Board of the Warsaw Medical University (no. AKBE/24/16). All ethical approvals for the study have been obtained according to Polish regulations.

DNA isolation and PCR amplification {#Sec4}
-----------------------------------

Genomic DNA was isolated from whole blood using the DNeasy Blood and Tissue kit (Qiagen, Crawley, United Kingdom). Detection of tick-borne pathogens was performed by amplification and sequencing of different loci: (1) the flagellin gene (*flaB*) and the *16S rRNA* gene for *Borrelia* spp. \[[@CR34], [@CR35]\]; (2) the glycerophosphodiester phosphodiesterase (*glpQ*) gene for *B. myiamotoi* \[[@CR36]\]; (3) the *18S rRNA* gene of *Babesia* spp. \[[@CR37]\]; (4) the citrate synthase (*gltA*) gene for *Rickettsia* spp. \[[@CR38]\]; (5) the *16S rRNA* gene and *groESL* heat shock operon for *A. phagocytophilum*, as well as Ca. *Neoehrlichia* spp. \[[@CR39], [@CR40]\]. Negative controls were performed in the absence of template DNA. *Anaplasma phagocytophilum*, Ca. Neoehrlichia mikurensis, *Borrelia afzelii*, *B. garinii* and *B. myiamotoi* DNA extracted from blood of positive patients diagnosed in AmerLab Ltd. Diagnostic Laboratory of Parasitic Diseases and Zoonotic Infections, *Babesia microti* King College strain DNA isolated from BALB/c mice blood and *Rickettsia helvetica* DNA obtained from infected tick were used as positive controls. Amplicons were visualized with Midori Green stain (Nippon Genetics Europe GmbH) following electrophoresis in 2% agarose gels. Amplicons were purified and sequenced by a private company (Genomed S.A., Poland) in both directions.

Phylogenetic analysis {#Sec5}
---------------------

Obtained nucleotide sequences were analyzed using BLAST-NCBI and MEGA v. 7.0 software \[[@CR41]\] for sequence alignment, species typing and phylogenetic relationships. After testing the data for the best substitution model, phylogenetic trees were obtained using Maximum Likelihood as the tree construction method and Tamura 92 + I parameter algorithm as a distance method. For comparison, sequences of *Anaplasma* spp. obtained from GenBank ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)) were implemented in the sequence alignment. The stability of inferred phylogenies was assessed by bootstrap analysis of 1000 randomly generated sample trees.

Serological tests {#Sec6}
-----------------

All patient serum samples were analyzed for antibodies against tick-borne pathogens by using: (i) *Borrelia* IgM and IgG ELISA tests (Biomedica Laboratories, Vienna, Austria) (ii) Western Blot: *recom*Line *Borrelia* IgM and *recom*Line *Borrelia* IgG (Microgen, Neuried, Germany) for *Borrelia burgdorferi* s.l.; (iii) *Ehrlichia chaffeensis* and *Anaplasma phagocytophilum* IFA IgM Antibody Kit (Fuller Laboratories, California, the USA) for *Anaplasma phagocytophilum*; (iv) *Babesia microti* IFA IgM and IgG antibody kits (Fuller Laboratories, California, the USA) for *Babesia* spp.; (v) Spotted Fever *Rickettsia* IgG EIA antibody kit (Fuller Laboratories, California, the USA) for *Rickettsia* spp. with the manufacturer's cut-off levels and interpretation criteria.

New sequences {#Sec7}
-------------

New nucleotide sequences have been deposited in GenBank with the accession numbers: MG570466 for *groESL* of *A. phgocytophilum* and MG570467 for *flaB* of *B. garinii*.

Results {#Sec8}
=======

In total 148 blood samples from asymptomatic HIV-positive patients were included, predominantly male (140 patients, 95%) with mean age of 33 years. The median lymphocyte CD4+ T cell count was 465/μl with 19% of patients with less than 300/μl. Most of these patients (82%; *n* = 121) were on HAART.

Among the 148 studied blood samples two cases (1.4%) of infection with tick-borne pathogen were reported.Patient 1. A 31-year-old man from Georgia, diagnosed with HIV in 2011 and HCV in 2009. Laboratory tests showed elevated liver enzyme levels, plasma HIV RNA levels of 6938 copies/ml and a CD4+ T cell count of 534/μl. The patient was hospitalized in 2013 due to infection of the urinary tract and in 2014 because of heart arrhythmia not confirmed in ECG. The patient had no history of tick bite and no clinical manifestation characteristic for tick-borne diseases.

The PCR analysis revealed the presence of *A. phagocytophilum-*specific 540 bp fragment of the *16S rRNA* gene and the 1200 bp fragment of the *groESL* heat shock operon. Sequencing analysis of the PCR products using both sets of primers showed a high level of homology (\< 99.8%) with *A. phagocytophilum* strains pathogenic for humans and animals (Fig. [1](#Fig1){ref-type="fig"}). The tests revealed the presence of specific IgM and IgG antibodies against *A. phagocytophilum* using indirect immunofluorescence assay (IFA). The DNAs presence of *Borrelia* spp., *Babesia* spp., *Rickettsia* spp. and CNM was not confirmed. The results of a serological test for the above-mentioned tick-borne pathogens (excluding CNM and *B. myiamotoi*) were also negative.Patient 2. 25-year-old man, diagnosed with HIV in 2013. The patient had been using HAART since 2013. Laboratory tests showed lymphocyte CD4+ T cell count of 424/μl, plasma HIV RNA load was undetectable. Routine laboratory tests showed no signs of any infection. He was diagnosed and treated with syphilis twice. He had no history of tick bites, rash, erythema migrans or other signs of early or late-stage Lyme borreliosis.Fig. 1Phylogenetic tree of the *Anaplasma* isolate studied in the current work and chosen isolates from GenBank based on the fragment of the groESL heat shock operon. Numbers at the nodes of the tree indicate bootstrap values (1000 replicates)

A 357 bp fragment of *Borrelia 16S rRNA* gene was amplified from the patient's blood by PCR. The partial *flaB* fragment (600 bp) was also amplified since the *16S rRNA* gene is too conserved for analysis of *Borrelia* genetic heterogeneity. Alignment and BLAST-NCBI analyses of *16S rRNA* and *flaB* gene fragments revealed the presence of *B. garinii* identical to isolates obtained from *Ixodes ricinus* in Poland (*flaB*: HM345898) and the Czech Republic (*flaB:* JN828685), as well as from ticks in Spain (*16S rRNA*: DQ147793) and Russia (*16S rRNA*: KY346891).

The results of serological tests (ELISA and WB) were ambiguous: for IgM antibodies, ELISA test was 13.5 BBU/ml (not confirmed by WB: Op.), for IgG antibodies the test results were indeterminate (ELISA: 9 BBU/ml; WB: 6p.). The DNAs presence of *A. phagocytophilum*, *Babesia* spp., *Rickettsia* spp. and CNM was not confirmed. The results of a serological test for the above-mentioned tick-borne pathogens (excluding CNM and *B. myiamotoi*) were also negative.

Discussion {#Sec9}
==========

Till now studies investigating the epidemiology of tick-borne pathogen infection have focused on healthy individuals with normal immunological function and living in endemic regions or clinical findings among hospitalized patients. In HIV-positive patients, where a serological diagnosis is complicated due to reduced positive predictive value, a method where the microorganism detected directly might be of great value \[[@CR11]\]. Hence, we conducted a retrospective, molecular study to ascertain the prevalence and incidence of tick-borne infections in HIV-infected persons with no clinical symptoms located in Poland, an endemic area for *I. ricinus* ticks. The diagnostic methods of tick-borne diseases used in this study are compatible with recommendation of Polish Society of Epidemiology and Infectious Diseases \[[@CR42]\].

The results of our study revealed the first case of a patient co-infected with HIV and *A. phagocytophilum* -- the agent of human granulocytic anaplasmosis (HGA). The patient had no history of tick bite or clinical manifestation of anaplasmosis. It is well known that the early symptoms of HGA are nonspecific, often mimicking a viral infection, as well as that almost a quarter of patients with proven HGA does not report exposure to ticks \[[@CR43]\]. However, the clinical range of HGA spans from asymptomatic infections to fatal diseases. Most published case reports indicate that HGA is a mild, self-limited illness that resolves without antibiotic treatment \[[@CR44]\]. Asymptomatic infection with *A. phagocytophilum* may occur frequently, as suggested in a seroepidemiologic study in which 30% of hunters in tick-endemic area seroconverted without symptoms \[[@CR45]\]. Serious opportunistic infections can occur in immunocompromised patients during the course of HGA and fatal cases of herpes simplex or *Candida albicans* esophagitis, as well as invasive pulmonary aspergillosis, are described \[[@CR46]--[@CR48]\]. Most patients with HGA present with non-specific changes in routine hematological and chemistry blood tests, e.g. leucopenia, thrombocytopenia and mild to moderate evaluation of hepatic transaminase activities, which has been also noted in our patient 1. However, it is difficult to define clearly whether observed elevated liver enzyme levels is caused by HGA or HCV infection.

HGA can be laboratory-confirmed by examination of peripheral blood smear, PCR or isolation of *A. phagocytophilum* in HL-60 promyelocytic leukemia cell cultures inoculated with acute phase blood during an early stage of infection as well as by serological tests (IFA) (3--6 weeks after infection) which can be confirmed by PCR \[[@CR49]\]. Our laboratory results of molecular and serological tests fulfilled the criteria for confirmation of anaplasmosis and suggested not acute stage of the illness. Nevertheless, *Anaplasma*-specific antibodies can persist for months or years in the absence of any clinical signs of infection. Thus, changes in antibody titers cannot be used as monitors of effective treatment or recovery \[[@CR50], [@CR51]\].

Molecular analyses have indicated that some strains/genetic variants of *A. phagocytophilum* that are pathogenic for humans and domestic animals, circulate widely in nature in different hosts and display different vector tropisms and degrees of host pathogenicity \[[@CR8], [@CR52], [@CR53]\]. Previous studies have revealed two distinct genetic lineages of *A. phagocytophilum*: (1) genetic variants detected in humans, ticks, dogs, horses, sheep and red deer from Europe and USA which are believed to be pathogenic; and (2) genetic variants isolated from ticks and roe deer in Europe that are probably non-zoonotic strains (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR8], [@CR52]\]. The results of our molecular and phylogenetic analysis strongly suggest that infection in this patient was acquired with pathogenic variant of *A. phagocytophilum* that is closely related to *A. phagocytophilum* strains isolated previously from human and ticks in Poland and belongs to zoonotic group of isolates known to be pathogenic for humans (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR8], [@CR53]\]. Interestingly, our previous studies demonstrated that the occurrence of zoonotic species/strains of *A. phagocythophilum* in *I. ricinus* ticks are mainly restricted to urban areas compared to natural habitants where tick abundance was significantly higher \[[@CR8]\].

Despite the high incidence of HIV, co-infection with *B. burgdorferi* is rarely reported in medical journals \[[@CR11], [@CR12]\]. The vast majority of cases involve typical Lyme neuroboreliosis symptoms, such as meningoradiculitis and facial palsy \[[@CR12]\]. Little is known about the course of Lyme neuroboreliosis in HIV patients, and the mechanism by which impaired immunity in HIV infection might influence the course of disease in Lyme neuroboreliosis still needs to be clarified. Animal models have shown that lymphocytes T CD4+ facilitate clearance of *B. burgdorferi* \[[@CR54]\] and immunodeficiency leads to higher spirochete burdens and higher infectivity of these bacteria \[[@CR55]\]. In HIV positive patients, the relatively higher HIV viral load in cerebrospinal fluid compared with plasma in the course of *B. burgdorferi* infection was observed \[[@CR12]\]. Our patient had no signs of early or late-stage Lyme borreliosis. However, *Borrelia garini* infection, the main agent of neuroborreliosis in Europe \[[@CR56]\], was confirmed by a positive PCR for the *16S rRNA* and *flaB* gene fragment. In our patient, the antibiotic treatment of syphilis could have a positive effect on *B. burgdorferi* infection.

There is a well-known cross-reactivity between the *Borrelia* and *Treponema* spirochetes and false positive serologic findings are described in patients with neurological infections with other spirochetes such as *T. pallidum* \[[@CR12], [@CR20]\]. In our case, the results of a serological test were indeterminate. Patients with syphilis and borreliosis may present with identical clinical symptoms. Therefore, clinicians frequently rely on serological criteria to differentiate between the two \[[@CR57]\]. The frequency of antibody detection in serum depends on the type of antigen used in the diagnostic test \[[@CR58]\]. *B. burgdorferi* s.l. and *T. pallidum* are spirochaetes which share antigens, such as the 41-kDa flagellin and the 60-kDa bacterial antigen. Anti-flagellin serum antibody can be detected in 87% of patients infected by *B. burgdorferi* and 75% of patients infected by *T. pallidum*. The frequency of antibody detection in the serum to the 60-kDa antigen is 58 and 42.9% for borreliosis and syphilis respectively \[[@CR58]\]. The flagellin is highly immunogenic and elicits the earliest detectable immune response after infection. This antigen's fractions of *B. burgdorferi* are often used in Lyme antibody assays to improve the sensitivity of tests \[[@CR58]\]. Nevertheless, these are false positive results in patients with syphilis \[[@CR20], [@CR57]\]. Accordingly, our data suggest that in patients with indeterminate Lyme screening and negative or indeterminate confirmatory testing, performance of PCR might be considered.

Conclusions {#Sec10}
===========

In this study, we presented two cases of tick-borne infection in HIV-positive patients. In both cases, the diagnoses were based on molecular and serological tests. No symptoms of tick-borne infection in the cases could be explained by antibiotic therapy recommended due to urinary tract infection (patient 1) or *Treponema palladium* infection (patient 2). Asymptomatic tick-borne infection can occur in HIV-positive patients. The detailed history of tick bites, especially in endemic tick areas, should be considered as part of anamnesis in routine clinical care of HIV-positive patients.

CNM

:   *Candidatus* Neoehrlichia mikurensis

ECG

:   Electrocardiography

ELISA

:   Enzyme-linked immunosorbent assay

EM

:   *Erythema migrans*

HAART

:   Highly active antiretroviral therapy

HCV

:   Hepatitis C virus

HGA

:   Human granulocytic anaplasmosis

HIV-1

:   Human immunodeficiency virus type 1

IFA

:   Immunofluorescent assay

iRBC

:   Infected red blood cells

LT

:   T lymphocyte

MSF

:   Mediterranean spotted fever

PPV

:   Positive predictive value

SFG

:   Spotted fever group

TBDs

:   Tick-borne diseases

WB

:   Western blot

Funding {#FPar1}
=======

This study was supported by the Ministry of Science and Higher Education, Grant Iuventus Plus IP2014050373.

Availability of data and materials {#FPar2}
==================================

All data analysed during this study are included in this published article. Representative sequences are submitted in the GenBank database under the accession numbers MG570466-MG570467.

The study was designed and performed by RWF and AP. RWF and MB participated in molecular analyses. AP and MS participated in serological analysis. JDK participated in collecting the material, analysis and interpretation of medical data. RWF and AP drafted the manuscript. RWF, AP and JDK revised critically of the manuscript for important intellectual content. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

Written informed consent was obtained from all patients and the study protocol followed ethical guidelines of the 2013 Declaration of Helsinki. The study was approved by the Internal Review Board of the Warsaw Medical University (no. AKBE/24/16). All ethical approvals for the study have been obtained according to Polish regulations.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar5}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
